Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [2065]

Delayed exposure to common infections causes acute childhood leukaemia

Dr Julia Hauer - Clinic for Pediatric Oncology, Haematology and Clinical...

Delayed exposure to common infections causes acute childhood leukaemia ( Dr Julia Hauer - Clinic for Pediatric Oncology, Haematology and Clinical Immunology, Düsseldorf, Germany )

Improving outcomes for oestrogen receptor positive breast cancer

Dr Giancarlo Pruneri - European Institute of Oncology, Milan, Italy

Improving outcomes for oestrogen receptor positive breast cancer ( Dr Giancarlo Pruneri - European Institute of Oncology, Milan, Italy )

ESMO ranking of the clinical benefits of new drugs

Prof Alberto Sobrero - Ospedale San Martino, Genova, Italy

ESMO ranking of the clinical benefits of new drugs ( Prof Alberto Sobrero - Ospedale San Martino, Genova, Italy )

Cancer and the workplace

Prof Diana Kloss - Manchester University, Manchester, UK

Cancer and the workplace ( Prof Diana Kloss - Manchester University, Manchester, UK )

Breast conservation therapy

Prof Virgilio Sacchini - European Institute of Oncology, Milan, Italy

Breast conservation therapy ( Prof Virgilio Sacchini - European Institute of Oncology, Milan, Italy )

Personalised medicine for rare cancers

Prof Paolo Casali - Università degli Studi di Milano, Milan, Italy

Personalised medicine for rare cancers ( Prof Paolo Casali - Università degli Studi di Milano, Milan, Italy )

Working With Cancer: helping people affected by cancer return to work

Mandy Goodman and Barbara Wilson - Working With Cancer

Working With Cancer: helping people affected by cancer return to work ( Mandy Goodman and Barbara Wilson - Working With Cancer )

Bendamustine for indolent lymphoma reduces relapse after 10 years

Dr Mathias Rummel - University of Giessen, Giessen, Germany

Bendamustine for indolent lymphoma reduces relapse after 10 years ( Dr Mathias Rummel - University of Giessen, Giessen, Germany )

ShortHER trastuzumab treatment of HER2 breast cancer: 9 weeks v 1 year

Prof Pierfranco Conte - Istituto Oncologico Veneto, Padova, Italy

ShortHER trastuzumab treatment of HER2 breast cancer: 9 weeks v 1 year ( Prof Pierfranco Conte - Istituto Oncologico Veneto, Padova, Italy )

T-VEC and checkpoint therapy for melanoma

Prof Robert Andtbacka - Huntsman Cancer Institute, Salt Lake City, USA

T-VEC and checkpoint therapy for melanoma ( Prof Robert Andtbacka - Huntsman Cancer Institute, Salt Lake City, USA )

Dacomitinib for EGFR positive lung cancer

Dr Tony Mok, The Chinese University of Hong Kong, Shatin, China

Dacomitinib for EGFR positive lung cancer ( Dr Tony Mok, The Chinese University of Hong Kong, Shatin, China )

Treating advanced melanoma with ipilimumab and HF10

Prof Robert Andtbacka - Huntsman Cancer Institute, Salt Lake City, USA

Treating advanced melanoma with ipilimumab and HF10 ( Prof Robert Andtbacka - Huntsman Cancer Institute, Salt Lake City, USA )

More from ecancer